A recent study reveals that people who stop using popular slimming jabs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who stop conventional lifestyle plans.
Published data in a leading health publication shows that while overweight people often shed substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such medications must be informed of the danger of fast rebound weight gain when the treatment ends," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a return to original mass in about 18 months.
Weighing Approaches
The research, which examined dozens of studies involving thousands of patients, compared the effects of these new drugs with other pills.
Scientists note that people who lose weight through lifestyle changes alone usually have a more gradual weight regain—approximately 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Doctors suggest the way of the jabs accounts for the accelerated weight return.
These medications copy a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Disease?
Health authorities advise the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Professionals contend that, given the significant potential of relapse, the treatment might need to be life-long.
This view is echoed by pharmaceutical companies, who note that the results "highlight the long-term nature of obesity," similar to managing diseases like diabetes.
User Experiences
People who have come off the jabs report a intense resurgence of appetite.
"It felt as if something that goes on and I was suddenly extremely hungry," recalled one woman.
This challenge is exacerbated if individuals have not established permanent lifestyle or habit modifications during therapy.
Significant Use
Figures suggest that millions of adults in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a standalone fix and maintained weight loss likely depends on ongoing behavioural changes.
